Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.66 |
| ▸ | DGKA | P23743 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15003750 | 0.91 | CASP2 (0.57) | CASP2DGKAL3MBTL1NAAAFAAH | |
| SCHEMBL23599342 | 0.89 | CASP2 (0.64) | CASP2DGKAL3MBTL1NAAAFAAH | |
| SCHEMBL13129294 | 0.87 | CASP2 (0.65) | CASP2L3MBTL1NAAAFAAHEPHX2 | |
| SCHEMBL2616859 | 0.86 | CASP2 (0.51) | CASP2DGKAL3MBTL1NAAAFAAH | |
| SCHEMBL21302767 | 0.85 | DGKA (0.59) | CASP2DGKAL3MBTL1NAAAFAAH | |
| SCHEMBL20074549 | 0.84 | DGKA (0.54) | CASP2DGKAL3MBTL1NAAAFAAH | |
| SCHEMBL12627183 | 0.84 | TSHR (0.54) | CASP2DGKAL3MBTL1NAAAEPHX2 | |
| SCHEMBL20903685 | 0.84 | L3MBTL1 (0.65) | CASP2DGKAL3MBTL1NAAAFAAH | |
| SCHEMBL21467745 | 0.84 | L3MBTL1 (0.65) | CASP2DGKAL3MBTL1NAAAFAAH | |
| SCHEMBL21468095 | 0.84 | L3MBTL1 (0.65) | CASP2DGKAL3MBTL1NAAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170924-B1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | LIFE TECHNOLOGIES CORP (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20120252030-A1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | Life Technologies Corporation (US) | 2012-10-04 | — | — | US | disclosed |
| US-8163897-B2 | 5-bromo-2′-deoxy-uridine labeled nucleotide triphosphates and nucleic acid probes and methods of making and using the same | APPLIED BIOSYSTEMS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110207920-A1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | Life Technologies Corporation (US) | 2011-08-25 | — | — | US | disclosed |
| US-7915392-B2 | 5-bromo-2′-deoxy-uridine labeled nucleotide triphosphates and nucleic acid probes and methods of making and using the same | Life Technologies Corporation (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915392-B2 | 5-bromo-2′-deoxy-uridine labeled nucleotide triphosphates and nucleic acid probes and methods of making and using the same | Life Technologies Corporation (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090325158-A1 | 5-Bromo-2'-Deoxy-Uridine Labeled Nucleotide Triphosphates and Nucleic Acid Probes and Methods of Making and Using the Same | APPLERA CORPORATION (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325158-A1 | 5-Bromo-2'-Deoxy-Uridine Labeled Nucleotide Triphosphates and Nucleic Acid Probes and Methods of Making and Using the Same | APPLERA CORPORATION (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2008157311-A2 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | APPLERA CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207920-A1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | DUT, PCNA, TK1 | CASP2 973/4885DGKA 1079/4885L3MBTL1 1497/4885 |
| US-20090325158-A1 | 5-Bromo-2'-Deoxy-Uridine Labeled Nucleotide Triphosphates and Nucleic Acid Probes and Methods of Making and Using the Same | DUT, PCNA, TK1 | CASP2 973/4885DGKA 1079/4885L3MBTL1 1497/4885 |
| US-20120252030-A1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | DUT, PCNA, TK1 | CASP2 973/4885DGKA 1079/4885L3MBTL1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.